Results 71 to 80 of about 75,890 (310)

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis, F. Y. Coxon, J. S. Graham, K. Boyd, L. R. Wall, M. Highley, M. M. Eatock, P. Bützberger-Zimmerli, S. Harden, T. R. J. Evans, T. S. Maughan   +10 more
core   +1 more source

Efficacy and Safety Assessment of 5‐Fluorouracil, Irinotecan and Oxaliplatin‐Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy

Advanced Materials, EarlyView.
A novel FIRINOX‐loaded implant demonstrates controlled drug release, and potent therapeutic efficacy in pancreatic ductal adenocarcinoma mouse models with safety confirmed in a large‐animal pre‐clinical model. This innovative drug delivery platform offers a promising new treatment approach for non‐resectable, treatment‐resistant pancreatic cancer ...
Samantha J. Wade, Ashna A. Kumar, Samuel O. Nitschke, Paul Joyce, Elahe Minaei, Stephanie E. Reuter, Chelsea Penney, Holly Warren, Ruby Shepherd, Jeremy N. Dinoro, Gordon G. Wallace, Anthony Dosseto, Sameera Ansar, Naila Islam, Alistair Lochhead, George Sharbeen, Phoebe A. Phillips, Morteza Aghmesheh, Wayne J. Hawthorne, Kara L. Vine‐Perrow   +19 more
wiley   +1 more source

Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. [PDF]

, 2015
Squamous cell carcinoma of the cervix, highly prevalent in the developing world, is often metastatic and treatment resistant with no standard treatment protocol.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Mii, Sumiyuki, Miwa, Shinji, Momiyama, Masashi, Murakami, Takashi, Murata, Takuya, Tanaka, Kuniya, Uehara, Fuminari, Yamamoto, Mako, Yano, Shuya, Zhang, Nan, Zhang, Yong   +17 more
core   +7 more sources

Repeated irreversible electroporation in a locally advanced pancreatic cancer

Исследования и практика в медицине, 2022
It is reasonable to consider the technical possibility and oncological feasibility of the local tumor destruction in patients with locally advanced pancreatic cancer (PCa).
A. N. Polyakov, D. V. Podluzhnyi, N. E. Kudashkin, I. S. Bazin, B. M. Medvedeva, A. Yu. Syskova, D. M. Kantieva, Yu. I. Patyutko   +7 more
doaj   +1 more source

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. [PDF]

, 2017
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Michael Pimienta, Michael Pimienta, Mouad Edderkaoui, Ruoxiang Wang, Stephen Pandol   +4 more
core   +2 more sources

Cross‐Scale Hierarchical Targeted Delivery System Based on Small‐Scale Magnetic Robots

Advanced Robotics Research, EarlyView.
This article reviews a cross‐scale hierarchical targeted delivery system that integrates magnetic continuum robots and magnetic microrobots. By combining rapid long‐range navigation with precise microscale targeting, the system overcomes key limitations of single‐scale approaches.
Junjian Zhou, Zhiqiang Chen, Yuanbiao Ma, Zhiqiang Tang, Qianqian Wang   +4 more
wiley   +1 more source

Evaluation of the Efficacy and Safety of FOLFOX in First-Line Treatment of Advanced Pancreatic Cancer

Journal of Oncological Sciences
Objective: In pancreatic cancer, only 15% to 20% of patients are potentially resectable at diagnosis. Current standard treatment for inoperable and metastatic patients includes: FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX regimens ...
Hüseyin ATACAN, Gül Sema YILDIRAN KESKİN, Gamze EMİN, Seda KAHRAMAN, Nurlan MAMMADZADE, Gizem YILDIRIM, Gökçe Gül GÜNEYSU, Berkan KARADURMUŞ, Esmanur KAPLAN TÜZÜN, Musa Barış AYKAN, İsmail ERTÜRK, Nuri KARADUMUŞ   +11 more
doaj   +1 more source

Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)

Journal of Pancreatology, 2021
. The incidence of pancreatic cancer has been rising worldwide, and its clinical diagnosis and treatment remain a great challenge. To present the update and improvements in the clinical diagnosis and treatment of pancreatic cancer in recent years ...
Yinmo Yang, Xueli Bai, Dapeng Bian, Shouwang Cai, Rufu Chen, Feng Cao, Menghua Dai, Chihua Fang, Deliang Fu, Chunlin Ge, Xiaochao Guo, Chunyi Hao, Jihui Hao, Heguang Huang, Zhixiang Jian, Gang Jin, Fei Li, Haimin Li, Shengping Li, Weiqin Li, Yixiong Li, Hongzhen Li, Tingbo Liang, Xubao Liu, Wenhui Lou, Yi Miao, Yiping Mou, Chenghong Peng, Renyi Qin, Chenghao Shao, Bei Sun, Guang Tan, Xiaodong Tian, Huaizhi Wang, Lei Wang, Wei Wang, Weilin Wang, Junmin Wei, Heshui Wu, Wenming Wu, Zheng Wu, Jingyong Xu, Changqing Yan, Xiaoyu Yin, Xianjun Yu, Chunhui Yuan, Taiping Zhang, Jixin Zhang, Jun Zhou, Yupei Zhao, on behalf of the Chinese Pancreatic Surgery Association   +50 more
doaj   +1 more source

Pancreatic Cancer: Multimodality treatment of locally advanced pancreatic cancer

Annals of Oncology, 1994
Summary Background The prognosis of locally advanced pancreatic cancer is poor (median survival 3–5 months). In view of the localized character of this disease several groups have explored the value of combined modality treatment. The conditions are that a good local treatment and an effective systemic treatment are available.
D.J.Th. Wagener, P.H.M. de Mulder, J.A. Wils   +2 more
openaire   +1 more source

Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer [PDF]

Radiation Oncology Journal, 2014
Survival outcome of locally advanced pancreatic cancer has been poor and little is known about prognostic factors of the disease, especially in locally advanced cases treated with concurrent chemoradiation. This study was to analyze overall survival and prognostic factors of patients treated with concurrent chemoradiotherapy (CCRT) in locally advanced ...
Kwak, Yoo-Kang, Lee, Jong Hoon, Lee, Myung-Ah, Chun, Hoo-Geun, Kim, Dong-Goo, You, Young Kyoung, Hong, Tae-Ho, Jang, Hong Seok   +7 more
openaire   +2 more sources